| 7.77 Data as of May 17 |  +0.21 / +2.78%Today’s Change | 5.42 Today|||52-Week Range 11.36 | -3.00% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $750.2M |
Achillion Pharmaceuticals, Inc. 300 George Street New Haven Connecticut 06511 |
| Mutual fund holders | 45.30% |
| Other institutional | 38.91% |
| Individual stakeholders | 23.47% |
| Michael D. Kishbauch, MBA | President, Chief Executive Officer & Director |
| Mary Kay Fenton, MBA, CPA | CFO, Secretary, SVP & Head-Investor Relations |
| Milind S. Deshpande, PhD | Chief Scientific Officer, President-R&D |
| Joseph Truitt, MBA | Chief Commercial Officer & Senior Vice President |
| Glenn Schulman | Head-Media Relations |
.
